Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about AZNCF
Recent news which mentions AZNCF
< Previous
1
2
3
4
5
6
7
Next >
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer
April 19, 2022
Tickers
AZN
AZNCF
DSKYF
DSNKY
Tags
DSNKY
News
General
From
Benzinga
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer
April 11, 2022
Tickers
AZN
AZNCF
BPMC
Tags
News
General
BPMC
From
Benzinga
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case
April 11, 2022
Tickers
AZN
AZNCF
DSKYF
DSNKY
Tags
Briefs
SGEN
Legal
From
Benzinga
AstraZeneca Bets $25M On Preclinical Bispecific Antibody
April 07, 2022
Tickers
AZN
AZNCF
Tags
AZNCF
Market News
Contracts
From
Benzinga
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
April 07, 2022
Tickers
AZN
AZNCF
BNTX
JNJ
Tags
Benzinga
NVAX
Biotech
From
Benzinga
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
April 06, 2022
Tickers
AZN
AZNCF
Tags
Trading Ideas
Briefs
AZN
From
Benzinga
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
April 04, 2022
Tickers
AZN
AZNCF
IONS
Tags
Briefs
Biotech
IONS
From
Benzinga
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld
March 24, 2022
Tickers
AZN
AZNCF
Tags
Health Care
Market News
AZNCF
From
Benzinga
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
March 24, 2022
Tickers
AZN
AZNCF
Tags
Phase 3 Trial
Health Care
Market News
From
Benzinga
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters
March 23, 2022
Tickers
AZN
AZNCF
MRK
Tags
Health Care
AZNCF
Market News
From
Benzinga
Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents
March 21, 2022
Tickers
AZN
AZNCF
BMY
Tags
Briefs
Benzinga
AZN
From
Benzinga
AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows
March 21, 2022
Tickers
AZN
AZNCF
Tags
Biotech
AZN
Benzinga
From
Benzinga
AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT
March 18, 2022
Tickers
AZN
AZNCF
Tags
COVID/19 Coronavirus
News
COVID/19 Vaccine
From
Benzinga
AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai
March 17, 2022
Tickers
AZN
AZNCF
Tags
Biotech
Legal
AZN
From
Benzinga
AstraZeneca's COVID-19 Therapy Approved In Britain As Preventive Option
March 17, 2022
Tickers
AZN
AZNCF
Tags
COVID/19 Coronavirus
News
General
From
Benzinga
Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody
March 16, 2022
Tickers
AZN
AZNCF
Tags
COVID/19 Coronavirus
News
General
From
Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
March 16, 2022
Tickers
AZN
AZNCF
BNTX
PFE
Tags
General
PFE
Top Stories
From
Benzinga
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
March 15, 2022
Tickers
AZN
AZNCF
MRK
Tags
News
General
Phase 3 Trial
From
Benzinga
FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition
March 14, 2022
Tickers
AZN
AZNCF
Tags
Briefs
AZN
Benzinga
From
Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
March 14, 2022
Tickers
AZN
AZNCF
MRK
MYGN
Tags
Briefs
MRK
Biotech
From
Benzinga
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
March 03, 2022
Tickers
AZN
AZNCF
SNY
Tags
Market News
AZNCF
Health Care
From
Benzinga
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
February 25, 2022
Tickers
AZN
AZNCF
GSK
VIR
Tags
Movers
Health Care
AZNCF
From
Benzinga
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows
February 23, 2022
Tickers
AZN
AZNCF
BNTX
PFE
Tags
News
PFE
General
From
Benzinga
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Tickers
AZN
AZNCF
RHHBY
TAK
Tags
Legal
AZN
TAK
From
Benzinga
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
February 22, 2022
Tickers
AZN
AZNCF
DSKYF
DSNKY
Tags
AZN
Trading Ideas
Briefs
From
Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
Tickers
AZN
AZNCF
GSK
PFE
Tags
Benzinga
GSK
Biotech
From
Benzinga
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters
February 16, 2022
Tickers
AZN
AZNCF
JNJ
MRNA
Tags
AZN
Briefs
MRNA
From
Benzinga
Why Are AstraZeneca Shares Trading Higher Today
February 15, 2022
Tickers
AZN
AZNCF
JNJ
MRK
Tags
Briefs
Trading Ideas
MRK
From
Benzinga
AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21
February 10, 2022
Tickers
AZN
AZNCF
Tags
Dividends
Earnings
Guidance
From
Benzinga
AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences
February 03, 2022
Tickers
AZN
AZNCF
Tags
News
General
Health Care
From
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.